CALDIAMIDE SODIUM
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 419.0 | -3.4 | 5 | 8 | 180.0 | 16 | 0.69 |
- CAS
- 122760912
- UNII
- 1M6415C70M
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 26 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00908310 | 2009-05-01 | Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) | Phase 4 | Completed |
| NCT00209443 | 2004-09-01 | A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-Iliac Arteries While Using Gadodiamide | Phase 3 | Completed |
| NCT00209391 | 2003-09-01 | A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide | Phase 3 | Completed |